|
39 Companies |
|
49 Products |
|
49 Products |
|
46 Mechanisms of Action |
|
0 Trials |
|
259 News |
|
| «123456» |
- | Pozenveo (poziotinib) / Assertio
New P2 trial, Monotherapy: NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma (clinicaltrials.gov) - Mar 25, 2013
P2, N=40, Recruiting, Sponsor: National OncoVenture
- | Trial completion, Surgery: Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 25, 2013
P3, N=3300, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Active, not recruiting --> Completed
- |||||||||| Gilotrif (afatinib) / Boehringer Ingelheim
New P3 trial, Metastases: ADAM-Afatinib Diarrhea Assessment and Management (clinicaltrials.gov) - Mar 18, 2013
P3, N=80, Recruiting, Sponsor: Boehringer Ingelheim
- | Avastin (bevacizumab) / Roche
Trial initiation date, Metastases: Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 25, 2013
P2/3, N=842, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Jul 2001 --> Aug 2002
- | Enrollment change, Surgery, Metastases: Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Feb 25, 2013
P3, N=840, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2001 --> Aug 2002 N=620 --> 840
- |||||||||| ganetespib (ADX-1612) / Aldeyra
New P3 trial, Combination therapy, Metastases: Galaxy 2: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (clinicaltrials.gov) - Feb 21, 2013
P3, N=500, Recruiting, Sponsor: Synta Pharmaceuticals Corp.
- erlotinib / Generic mfg.
Trial termination: Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 30, 2013
P1, N=48, Terminated, Sponsor: National Cancer Institute (NCI)
N=620 --> 840 Completed --> Terminated; Administratively complete.
- cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial termination: S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 27, 2013
P2, N=33, Terminated, Sponsor: Southwest Oncology Group
Completed --> Terminated; Administratively complete. Completed --> Terminated; This study was closed early due to poor accrual.
- Avastin (bevacizumab) / Roche
Trial termination, Metastases: Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 22, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; This study was closed early due to poor accrual. Completed --> Terminated
- Avastin (bevacizumab) / Roche
Trial initiation date, Metastases: Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 22, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Aug 2005 --> Jun 2006
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Surgery: Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 15, 2013
P3, N=500, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2005 --> Jun 2006 N=345 --> 500
- | Xalkori (crizotinib) / Pfizer
Enrollment change, Metastases: Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer (clinicaltrials.gov) - Jan 10, 2013
P1/2, N=27, Completed, Sponsor: Pfizer
N=345 --> 500 N=175 --> 27
- cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial termination, Surgery: SWOG-S0332: Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 25, 2012
P3, N=19, Terminated, Sponsor: Radiation Therapy Oncology Group
N=175 --> 27 Completed --> Terminated; This study terminated early due to low accrual.
- carboplatin / Generic mfg., paclitaxel / Generic mfg., gefitinib / Generic mfg.
Enrollment change: Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 18, 2012
P2, N=144, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; This study terminated early due to low accrual. N=63 --> 144
- | sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 17, 2012
P2, N=11, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
N=63 --> 144 N=20 --> 11
- | sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 17, 2012
P2, N=11, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
N=20 --> 11 Recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 11, 2012
P1, N=60, Completed, Sponsor: University of Washington
Recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly
Trial completion: Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 9, 2012
P2, N=109, Completed, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Vizimpro (dacomitinib) / Pfizer
Enrollment closed, Metastases: Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung (clinicaltrials.gov) - Dec 4, 2012
P2, N=119, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cisplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Surgery: SWOG-S0332: Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 26, 2012
P3, N=19, Terminated, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting N=574 --> 19
- bortezomib / Generic mfg.
Enrollment open, Metastases: Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer (clinicaltrials.gov) - Nov 19, 2012
P2, N=74, Recruiting, Sponsor: National Cancer Institute (NCI)
N=574 --> 19 Completed --> Recruiting
- buparlisib (AN2025) / Novartis, Adlai Nortye
New P1 trial, Combination therapy, Metastases: PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 6, 2012
P1, N=39, Recruiting, Sponsor: City of Hope Medical Center
- Trial termination, Metastases: SWOG S0229: S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer (clinicaltrials.gov) - Oct 30, 2012
P=N/A, N=2, Terminated, Sponsor: Southwest Oncology Group
Completed --> Recruiting Completed --> Terminated; Closed early due to poor accrual.
- Enrollment change, Metastases: SWOG S0229: S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer (clinicaltrials.gov) - Oct 30, 2012
P=N/A, N=2, Terminated, Sponsor: Southwest Oncology Group
Completed --> Terminated; Closed early due to poor accrual. N=164 --> 2
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 29, 2012
P1, N=24, Terminated, Sponsor: Southwest Oncology Group
N=164 --> 2 Active, not recruiting --> Terminated; Study closed early due to poor accrual.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 29, 2012
P1, N=24, Terminated, Sponsor: Southwest Oncology Group
Active, not recruiting --> Terminated; Study closed early due to poor accrual. N=75 --> 24
- erlotinib / Generic mfg.
Trial completion, Metastases: S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 29, 2012
P2, N=65, Completed, Sponsor: National Cancer Institute (NCI)
N=75 --> 24 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 29, 2012
P2, N=242, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change, Metastases: S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 4, 2012
P2, N=204, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=160 --> 204
- Trial completion, Metastases: S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 4, 2012
P2, N=204, Completed, Sponsor: Southwest Oncology Group
N=160 --> 204 Active, not recruiting --> Completed
- carboplatin / Generic mfg., erlotinib / Generic mfg.
Enrollment closed, Surgery: Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Sep 5, 2012
P2, N=76, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 26, 2012
P1, N=18, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting N=24 --> 18
- New P1 trial: Photodynamic Therapy in Treating Patients With Lung Cancer (clinicaltrials.gov) - Aug 16, 2012
P1, N=17, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
- paclitaxel / Generic mfg.
Trial completion: Paclitaxel in Treating Patients With Lung Cancer (clinicaltrials.gov) - Jun 28, 2012
P2, N=25, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=24 --> 18 Active, not recruiting --> Completed
- | carboplatin / Generic mfg., cisplatin / Generic mfg.
Trial completion, Surgery: Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 28, 2012
P3, N=640, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| pemetrexed / Generic mfg., sorafenib / Generic mfg.
Trial completion, Metastases: Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 16, 2012
P2, N=104, Completed, Sponsor: North Central Cancer Treatment Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cisplatin / Generic mfg., gefitinib / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: SAKK 19/03: Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 1, 2012
P2, N=63, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| erlotinib / Generic mfg.
New P4 trial, Metastases: A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations (clinicaltrials.gov) - May 30, 2012
P4, N=62, Active, not recruiting, Sponsor: Hoffmann-La Roche
- Avastin (bevacizumab) / Roche
New P2 trial, Metastases: GASTO 1001: Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma (clinicaltrials.gov) - Apr 29, 2012
P2, N=36, Recruiting, Sponsor: Si-Yu Wang
- topotecan / Generic mfg., vinorelbine tartrate / Generic mfg.
Trial completion, Combination therapy: Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer (clinicaltrials.gov) - Apr 25, 2012
P1, N=36, Completed, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | cisplatin / Generic mfg., pemetrexed / Generic mfg., erlotinib / Generic mfg.
New P2 trial: Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases (clinicaltrials.gov) - Apr 15, 2012
P2, N=60, Recruiting, Sponsor: Guangzhou Medical University
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (clinicaltrials.gov) - Apr 15, 2012
P2, N=60, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Trial initiation date: Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Initiation date: Aug 2011 --> Mar 2012
- | pemetrexed / Generic mfg., erlotinib / Generic mfg.
New P2 trial, Metastases: Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov) - Mar 26, 2012
P2, N=123, Completed, Sponsor: Si-Yu Wang
- carboplatin / Generic mfg., thalidomide / Generic mfg., paclitaxel / Generic mfg.
Trial termination: Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 22, 2012
P3, N=589, Terminated, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2011 --> Mar 2012 Active, not recruiting --> Terminated; Trial was stopped early for futility
- ||||| picropodophyllin (AXL1717) / Axelar
New P2 trial, Metastases: Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung (clinicaltrials.gov) - Mar 21, 2012
P2, N=100, Completed, Sponsor: Axelar AB
- Orplatna (satraplatin) / Yakult Honsha, Agennix, BMS
Trial termination, Metastases: Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy (clinicaltrials.gov) - Mar 20, 2012
P1/2, N=20, Terminated, Sponsor: Agennix
Active, not recruiting --> Terminated; Trial was stopped early for futility Active, not recruiting --> Terminated; Sponsor decided to discontinue study drug development.
- Orplatna (satraplatin) / Yakult Honsha, Agennix, BMS
Enrollment change, Metastases: Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy (clinicaltrials.gov) - Mar 20, 2012
P1/2, N=20, Terminated, Sponsor: Agennix
Active, not recruiting --> Terminated; Sponsor decided to discontinue study drug development. N=30 --> 20
- Neulasta (pegfilgrastim) / Roche
New P2 trial, Metastases: Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 18, 2012
P2, N=45, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
- Zyflo (zileuton) / Chiesi
Trial completion, Metastases: Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 14, 2012
P2, N=140, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=30 --> 20 Active, not recruiting --> Completed